Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Current Leases (2019 - 2025)

Celldex Therapeutics (CLDX) has 7 years of Current Leases data on record, last reported at $1.6 million in Q4 2025.

  • For Q4 2025, Current Leases rose 6.89% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, up 6.89%, while the annual FY2025 figure was $1.6 million, 6.89% up from the prior year.
  • Current Leases reached $1.6 million in Q4 2025 per CLDX's latest filing, roughly flat from $1.6 million in the prior quarter.
  • Across five years, Current Leases topped out at $1.8 million in Q1 2022 and bottomed at $1.3 million in Q2 2021.
  • Average Current Leases over 5 years is $1.5 million, with a median of $1.5 million recorded in 2023.
  • The widest YoY moves for Current Leases: up 31.57% in 2021, down 18.43% in 2021.
  • A 5-year view of Current Leases shows it stood at $1.7 million in 2021, then dropped by 17.24% to $1.4 million in 2022, then increased by 11.7% to $1.6 million in 2023, then decreased by 10.04% to $1.5 million in 2024, then rose by 6.89% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $1.6 million in Q4 2025, $1.6 million in Q3 2025, and $1.5 million in Q2 2025.